Atlas Trials

2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen

Clinical trial NCT00191971 · COMPLETED

Trial details

NCT number
NCT00191971
Sponsor
Eli Lilly and Company
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Urologic NeoplasmsCarcinoma, Transitional Cell
Start date
2004-01-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.